LOS ANGELES, Aug 30 (Reuters) - Biotechnology company Ligand Pharmaceuticals Inc. (LGND.OQ: Quote, Profile, Research) said on Wednesday that it is slashing the monthly salary of Chairman and interim Chief Executive Henry Blissenbach to $40,000 from $75,000 “upon review of additional facts and circumstances.”
